{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-040458","form_type":"8-K","ticker":"APTN","cik":"0001938571","company_name":"ADAPTIN BIO, INC.","filed_at":"2026-04-06T23:59:59+00:00","discovered_at":"2026-05-14T18:02:33.300702+00:00","generated_at":"2026-05-15T07:26:37.223976+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"Adaptin Bio shares approved for OTCQB quotation under ticker APTN","bullets":["Common shares approved for quotation on OTCQB Venture Market; ticker symbol APTN.","Trading expected to begin within the next 6-8 weeks, pending any material updates.","CEO notes lead program APTN-101 is expected to begin a Phase 1 first-in-human trial shortly.","Company develops precision cancer therapeutics targeting brain and difficult-to-reach tissues."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-040458","json":"https://secwatch.observer/filing/0001213900-26-040458.json","markdown":"https://secwatch.observer/filing/0001213900-26-040458.md","text":"https://secwatch.observer/filing/0001213900-26-040458.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/0001213900-26-040458-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1938571/000121390026040458/ea0285223-8k_adaptin.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:26:37.223976+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}